As per attachment.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Norris Medicines Ltd reported audited standalone financial results for FY ended March 2026. Revenue from operations grew 39.7% to Rs. 813.20 Lakhs from Rs. 582.02 Lakhs in FY2025. However, the company continues to incur losses - PBT stood at negative Rs. 28.06 Lakhs (improved from negative Rs. 117.81 Lakhs) and PAT at negative Rs. 28.06 Lakhs (improved from negative Rs. 123.75 Lakhs). The auditors from Bahedia & Associates issued an unmodified opinion. Operating cash flow for the year was negative at Rs. 11.26 Lakhs. Total equity stands at negative Rs. 1514.80 Lakhs, indicating negative net worth. The Board also appointed M/s. Dhiren Y Parikh & Co. as Internal Auditors for FY 2026-27.
Despite revenue growth, the company remains deeply loss-making with negative net worth and negative operating cash flows. Shareholders face significant risk as accumulated losses exceed paid-up capital. Any recovery will require sustained improvement in profitability and cash generation.